Kitov Pharma is an innovative pharmaceutical drug development company. Leveraging deep regulatory and clinical-trial expertise, Kitov’s veteran team of healthcare professionals maintains a proven track record in streamlined end-to-end drug development and approval.

Kitov’s combination drug, Consensi™, is indicated to treat osteoarthritis pain and hypertension simultaneously. The U.S. Food & Drug Administration (FDA) approved Consensi™ oral tablets for marketing on May 31, 2018. In January 2019, Kitov announced the signing of an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for commercialization of the drug in the US market. The agreement is Kitov’s third licensing and distribution agreement, following previously signed deals covering China and South Korea.

Kitov’s newest drug, NT-219, is a novel patented small molecule that targets IRS1/2 and STAT3 – two signal proteins that are part of an anti-cancer drug resistance mechanism. Based on recent findings, Kitov researchers demonstrated that NT-219 binds directly to the two proteins. In previous preclinical models where NT-219 was administered in combination with various oncology therapies, outstanding efficacy in preventing acquired resistance and reversing tumor resistance was demonstrated.

By lowering development risk and cost through fast-track regulatory approval of novel therapeutics, Kitov plans to deliver a rapid ROI and long-term potential to investors, while making a meaningful impact on people’s lives.

Founded in 2010, Kitov became a public company in 2013 when its shares were first traded on the Tel Aviv Stock Exchange (TASE). Kitov successfully issued an IPO on NASDAQ in November 2015. The company currently trades on both stock exchanges.